Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
Over one billion people have received 2-3 dosages of an inactivated COVID-19 vaccine for basic immunization. Whether a booster dose should be delivered to protect against the Omicron variant and its sub-lineages, remains controversial. Here, we tested different vaccine platforms targeting the ancestral or Omicron strain as a secondary booster of the ancestral inactivated vaccine in mice. We found that the Omicron-adapted inactivated viral vaccine promoted a neutralizing antibody response against Omicron in mice. Furthermore, heterologous immunization with COVID-19 vaccines based on different platforms remarkably elevated the levels of cross- neutralizing antibody against Omicron and its sub-lineages. Omicron-adapted vaccines based on heterologous platforms should be prioritized in future vaccination strategies to control COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - 12(2023), 1 vom: 14. Dez., Seite e2143283 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Jianyang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 14.12.2022 Date Revised 21.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/22221751.2022.2143283 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348907567 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348907567 | ||
| 003 | DE-627 | ||
| 005 | 20231226041359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2022.2143283 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348907567 | ||
| 035 | |a (NLM)36377297 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Jianyang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Over one billion people have received 2-3 dosages of an inactivated COVID-19 vaccine for basic immunization. Whether a booster dose should be delivered to protect against the Omicron variant and its sub-lineages, remains controversial. Here, we tested different vaccine platforms targeting the ancestral or Omicron strain as a secondary booster of the ancestral inactivated vaccine in mice. We found that the Omicron-adapted inactivated viral vaccine promoted a neutralizing antibody response against Omicron in mice. Furthermore, heterologous immunization with COVID-19 vaccines based on different platforms remarkably elevated the levels of cross- neutralizing antibody against Omicron and its sub-lineages. Omicron-adapted vaccines based on heterologous platforms should be prioritized in future vaccination strategies to control COVID-19 | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Omicron variant | |
| 650 | 4 | |a booster vaccine | |
| 650 | 4 | |a heterologous vaccination | |
| 650 | 4 | |a neutralizing antibody | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 650 | 7 | |a Broadly Neutralizing Antibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a He, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Lianlian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a An, Chaoqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Lifang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jialu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Ziyang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zhongfang |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Zhenglun |e verfasserin |4 aut | |
| 700 | 1 | |a Mao, Qunying |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Miao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 12(2023), 1 vom: 14. Dez., Seite e2143283 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:1 |g day:14 |g month:12 |g pages:e2143283 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2022.2143283 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 1 |b 14 |c 12 |h e2143283 | ||